Familial Pancreatic Cancer PROPHilation Program in Italy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAssociazione Italiana per lo Studio del Pancreas
About this trial
The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.
Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.
Up to 3,000 participants will be enrolled in this study.
Eligibility criteria
Qualifiers
Being enrolled on the IRFARPC registry
Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
Willingness to participate in saliva-swab-based genetic testing
Disqualifiers
None
Trial design
Treatments tested in this trial
- Saliva swab testing
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Associazione Italiana per lo Studio del Pancreas
Lead sponsor
General and Pancreatic Surgery Unit, University of Verona
Collaborator
Fondazione Valsecchi
Collaborator
Associazione Oltre La Ricerca
Collaborator
Genomica srl
Collaborator
Source ClinicalTrials.gov